Pharmacogenomics of cetuximab in metastatic colorectal carcinoma

Antonio Russo, Riccardo Giampieri, Fotious Loupakis, Vito Lorusso, Stefano Cascinu, Anna Elisabetta Brunetti, Emanuela Dell'Aquila, Mario Scartozzi, Mario Scartozzi, Bruno Vincenzi, Nicola Silvestris, Alfredo Falcone, Giuseppe Tonini, Daniele Santini, Daniele Santini

Risultato della ricerca: Articlepeer review

4 Citazioni (Scopus)


Cetuximab is a chimeric monoclonal antibody that has revolutionized the treatment of metastatic colorectal cancer. Knowledge of the mechanisms that underlie its effectiveness, as well as the primary and secondary resistance mechanisms, have led to important developments in the understanding of cetuximab biology. In light of knowledge gained from recent trials, the efficacy of cetuximab has been clearly demonstrated to depend upon RAS mutational status, moreover cetuximab should only be used in a subset of patients who may benefit. In this article, we critically review clinical and pharmacogenetic issues of cetuximab, focusing on the cost-effectiveness involved with the use of the drug.
Lingua originaleEnglish
pagine (da-a)1701-1715
Numero di pagine15
Stato di pubblicazionePublished - 2014

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.1300.1313???
  • ???subjectarea.asjc.1300.1311???
  • ???subjectarea.asjc.3000.3004???


Entra nei temi di ricerca di 'Pharmacogenomics of cetuximab in metastatic colorectal carcinoma'. Insieme formano una fingerprint unica.

Cita questo